Trial Profile
ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ViiV Healthcare
- 22 Oct 2021 Status changed from active, no longer recruiting to completed.
- 27 Jul 2020 Status changed from suspended to active, no longer recruiting.
- 23 Dec 2019 Planned primary completion date changed from 1 Oct 2021 to 29 Oct 2021.